In the BioHarmony Drug Report Database

"Preview" Icon

Diltiazem

Cardizem, Cardizem Cd, Cardizem La, Cardizem Sr, Dilacor, Diltiazem, Tiazac (diltiazem) is a small molecule pharmaceutical. Diltiazem was first approved as Cardizem on 1982-11-05. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target voltage-dependent L-type calcium channel subunit alpha-1C, 5-hydroxytryptamine receptor 3A, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily C member 1, Voltage-dependent L-type calcium channel subunit alpha-1F, potassium voltage-gated channel subfamily A member 1, potassium voltage-gated channel subfamily A member 7, cyclic nucleotide-gated cation channel alpha-3, voltage-dependent L-type calcium channel subunit alpha-1D, cGMP-gated cation channel alpha-1, cyclic nucleotide-gated cation channel beta-3, cyclic nucleotide-gated olfactory channel, and potassium voltage-gated channel subfamily A member 2. Diltiazem hydrochloride’s patent is valid until 2021-02-25 (FDA).

 

Trade Name

 

Cardizem, Cardizem Cd, Cardizem La, Cardizem Sr, Dilacor, Diltiazem, Tiazac
 

Common Name

 

diltiazem
 

ChEMBL ID

 

CHEMBL23
 

Indication

 

atrial fibrillation, atrial flutter, hypertension, myocardial infarction, supraventricular tachycardia, variant angina pectoris
 

Drug Class

 

Calcium channel blockers (diltiazem type)

Image (chem structure or protein)

Diltiazem structure rendering